Group 1 - The core point of the article is that Dongfang Biological has recently obtained medical device registration certificates for several time-resolved fluorescence immunoassay products in multiple countries, including the EU, Colombia, Indonesia, and Saudi Arabia [1] - The products include the "Calprotectin Quantitative Detection Kit" among others [1] - For the fiscal year 2024, the revenue composition of Dongfang Biological is projected to be 97.99% from the in vitro diagnostic industry and 2.01% from other businesses [1] - As of the report, Dongfang Biological has a market capitalization of 5.1 billion yuan [1]